CHF 50.00
In stock
AG-CN2-0454-M02020 mgCHF 50.00
AG-CN2-0454-M100100 mgCHF 95.00
More Information
Product Details
Synonyms VPC; (3α,16α)-Eburnamenine-14-carboxylic acid ethyl ester; Ethyl apovincaminate; RGH-4405; TCV 3B; AY 27255
Product Type Chemical


MW 350.5
Merck Index 14: 9991
CAS 42971-09-5
RTECS JW4792000
Source/Host Chemicals Semi-synthetic from Voacanga africana.
Purity Chemicals ≥98% (HPLC)
Appearance White to slightly yellow crystalline powder.
Solubility Soluble in DMSO, dichloromethane, acetone or 100% ethanol. Insoluble in water.
Identity Determined by 1H-NMR.
Smiles CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=C2)C(=O)OCC
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Selective Ca2+-calmodulin dependent cGMP-phosphodiesterase (PDE1) inhibitor. Shows vasorelaxant activity.
  • Neuroprotective agent.
  • Selectively inhibits voltage-sensitive Na2+ channels
  • Potent anti-inflammatory agent.
  • Inhibitor of NF-κB-dependent inflammatory responses by directly targeting IKK.
  • Shown to inhibit the NLRP3 inflammasome.
  • Antioxidant. Free radical scavenger.
  • Anticancer compound.
  • Anticonvulsant.
  • Attenuates osteoblastic differentiation of vascular smooth muscle cells.
  • Anti-schistosomal agent.
Product References
  1. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta: H.S. Ahn, et al.; Biochem. Pharmacol. 38, 3331 (1989)
  2. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine: J.E. Souness, et al.; Br. J. Pharmacol. 98, 725 (1989)
  3. Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation: M. Sitges & V. Nekrassov; Neurochem. Res. 24, 1585 (1999)
  4. In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine: B. Horvath, et al.; Clin. Neuropharmacol. 25, 37 (2002)
  5. Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons: K. Tarnok, et al.; Neurochem. Int. 53, 289 (2008)
  6. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor: R. Deshmukh, et al.; Eur. J. Pharmacol. 620, 49 (2009)
  7. Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism: K.I. Jeon, et al.; PNAS 107, 9795 (2010)
  8. Vinpocetine as a potent antiinflammatory agent: A.E. Medina, et al.; PNAS 107, 9921 (2010)
  9. Vinpocetine inhibits breast cancer cells growth in vitro and in vivo: E.W. Huang, et al.; Apoptosis 17, 1120 (2012)
  10. Vinpocetine attenuates lipid accumulation and atherosclerosis formation: Y. Cai, et al.; BBRC 434, 439 (2013)
  11. The anti-seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL-1beta and TNF-alpha expression in rat hippocampus: C.D. Gomez, et al.; J. Neurochem. 130, 770 (2014)
  12. Anti-inflammatory effects of vinpocetine in atherosclerosis and ischemic stroke: a review of the literature: L. Zhang & L. Yang; Molecules 20, 335 (2014)
  13. Vinpocetine inhibits amyloid-beta induced activation of NF-κB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells: R.T. Liu, et al.; Exp. Eye Res. 127, 49 (2014)
  14. Vinpocetine modulates metabolic activity and function during retinal ischemia: L. Nivison-Smith, et al.; Am. J. Physiol. Cell Physiol. 308, 737 (2015)
  15. Vinpocetine reduces lipopolysaccharide-induced inflammatory pain and neutrophil recruitment in mice by targeting oxidative stress, cytokines and NF-κB: K.W. Ruiz-Miyazawa, et al.; Chem. Biol. Interact. 237, 9 (2015)
  16. Vinpocetine attenuates osteoblastic differentiation of vascular smooth muscle cells: Y.Y. Ma, et al.; PLoS One 11, e0162295 (2016)
  17. A comparative study on the anti-schistosomal and hepatoprotective effects of vinpocetine and isosorbide-5-mononitrate on Schistosoma mansoni-infected mice: S.M. Alhusseiny, et al.; Acta Tropica 176, 114 (2017)
  18. Novel action of vinpocetine in the prevention of paraquat-induced parkinsonism in mice: involvement of oxidative stress and neuroinflammation: I.O. Ishola, et al.; Metab. Brain Dis. ahead of print, (2018)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.